A drug that AstraZeneca singled out as one of its key potential revenue growth drivers in the next decade has failed a pivotal study in light chain amyloidosis, a rare disease with few treatment ...

March is Myeloma Action Month, an opportunity to heighten awareness of plasma cell disorders and underscore the laboratory’s essential role in early detection, risk assessment, and longitudinal ...

Please provide your email address to receive an email when new articles are posted on . “Teclistamab has already been approved in multiple myeloma, and there is institutional data where it shows that ...

MM often goes undetected until its later stages because it presents with non-specific symptoms, including fatigue, weight loss, bone pain, and recurrent infections. 2,3 However, better awareness, ...